Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06193200 · ClinicalTrials.gov registry record · Phase 3
Evaluate the Neurological Effects of EryDex on Subjects With A-T
A Phase 3 study, sponsored by Quince Therapeutics S.p.A..
- Completed
- Registry status
- Phase 3
- Development phase
- 105
- Enrollment target
NCT06193200: Completed Phase 3 study, sponsored by Quince Therapeutics S.p.A..
NCT06193200 is a Phase 3 study that has completed, run by Quince Therapeutics S.p.A.. The registered enrollment target is 105 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06193200, a Phase 3 study, has completed, sponsored by Quince Therapeutics S.p.A..
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 105 participants
- Enrollment target
Study Summary
This is an international, multi-center, randomized, prospective, double-blind, placebo-controlled, Phase 3 study, designed to assess the effect of EryDex (dexamethasone sodium phosphate \[DSP\] in autologous erythrocytes), administered by intravenous (IV) infusion once every 28 days, on neurological symptoms of patients with Ataxia Telangiectasia (A-T).
Interventions
- OTHER Placebo
- DRUG Dexamethasone sodium phosphate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 105 participants |
| Start Date | 2024-06-24 |
| Est. Completion | 2025-12-17 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06193200
The ClinicalTrials.gov registry entry for NCT06193200 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 105 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Quince Therapeutics S.p.A., which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06193200 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06193200 about?
NCT06193200 is a clinical study titled "Evaluate the Neurological Effects of EryDex on Subjects With A-T". This is an international, multi-center, randomized, prospective, double-blind, placebo-controlled, Phase 3 study, designed to assess the effect of EryDex (dexamethasone sodium phosphate \[DSP\] in autologous erythrocytes), administered by intravenous (IV) infusion once every 28 days, on neurological...
What is the current status of trial NCT06193200?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 105 participants. The study started on 2024-06-24. Estimated completion is 2025-12-17.
What interventions are being tested in trial NCT06193200?
The interventions under investigation include: Placebo (OTHER), Dexamethasone sodium phosphate (DRUG).
Who is sponsoring clinical trial NCT06193200?
This trial is sponsored by Quince Therapeutics S.p.A., which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.